5.41
5.41 (0%)
As of Apr 17, 2025
Meiragtx Holdings Plc [MGTX]
Source:
Company Overview
Meiragtx Holdings Plc is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy.
| Country | United States |
| Headquarters | new york, new york |
| Phone Number | ( 646 ) 860-7985 |
| Industry | manufacturing |
| CEO | Alexandria Forbes, Ph.D. |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $33.3 |
| Operating Profit | $-164.2 |
| Net Income | $-147.8 |
| Net Cash | $-26.5 |
Profit Ratios
| Gross Margin | $9.5 |
| Operating Margin | -493.4 |
| Profit as % of Revenues | -6.4% |
| Profit as % of Assets | -49.6% |
| Profit as % of Stockholder Equity | -217.9% |
Management Effectiveness
| Return on Equity | -217.9% |
| Return on Assets | -54.8% |
| Turnover Ratio | 11.2% |
| EBITA | $-164.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $269.8 |
| Total Liabilities | $201.9 |
| Operating Cash Flow | $-104.5 |
| Investing Cash Flow | $23.5 |
| Financing Cash Flow | $54.5 |
